Patents Assigned to Oncternal Therapeutics, Inc.
-
Patent number: 11465987Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: GrantFiled: September 20, 2016Date of Patent: October 11, 2022Assignees: ONCTERNAL THERAPEUTICS, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Wei Li, Min Xiao, James Dalton, Sunjoo Ahn, Duane D Miller, Jin Wang
-
Patent number: 11285132Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.Type: GrantFiled: April 13, 2020Date of Patent: March 29, 2022Assignee: Oncternal Therapeutics, Inc.Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
-
Publication number: 20220024912Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: ApplicationFiled: July 8, 2021Publication date: January 27, 2022Applicants: ONCTERNAL THERAPEUTICS, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Wei LI, Min XIAO, James DALTON, Sunjoo AHN, Duane D. MILLER, Jin WANG
-
Patent number: 11084811Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: GrantFiled: February 21, 2019Date of Patent: August 10, 2021Assignees: ONCTERNAL THERAPEUTICS, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Wei Li, Min Xiao, James Dalton, Sunjoo Ahn, Duane D Miller, Jin Wang
-
Publication number: 20210024458Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: January 29, 2020Publication date: January 28, 2021Applicants: ONCTERNAL THERAPEUTICS, INC, University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Charles B. DUKE, Christopher C. COSS, Amanda JONES, James T. DALTON
-
Patent number: 10865196Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.Type: GrantFiled: January 16, 2018Date of Patent: December 15, 2020Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INC.Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
-
Patent number: 10849873Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.Type: GrantFiled: January 8, 2019Date of Patent: December 1, 2020Assignee: ONCTERNAL THERAPEUTICS, INCInventors: Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn, James T. Dalton
-
Publication number: 20200222365Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: August 30, 2019Publication date: July 16, 2020Applicant: Oncternal Therapeutics, Inc.Inventors: Ramesh NARAYANAN, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
-
Patent number: 10711008Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: June 3, 2019Date of Patent: July 14, 2020Assignee: Oncternal Therapeutics, Inc.Inventor: Stephen E. Webber
-
Patent number: 10646470Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.Type: GrantFiled: August 27, 2018Date of Patent: May 12, 2020Assignee: Oncternal Therapeutics, Inc.Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
-
Patent number: 10597354Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: October 5, 2018Date of Patent: March 24, 2020Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INCInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Charles B. Duke, Christopher C. Coss, Amanda Jones, James T. Dalton
-
Patent number: 10351569Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: August 18, 2017Date of Patent: July 16, 2019Assignee: Oncternal Therapeutics, Inc.Inventor: Stephen E. Webber
-
Patent number: 10159660Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.Type: GrantFiled: July 26, 2017Date of Patent: December 25, 2018Assignee: Oncternal Therapeutics, Inc.Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
-
Patent number: 9987251Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: November 21, 2016Date of Patent: June 5, 2018Assignee: Oncternal Therapeutics, Inc.Inventor: Jean-Michel Vernier
-
Patent number: 9895352Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: November 21, 2016Date of Patent: February 20, 2018Assignee: Oncternal Therapeutics, Inc.Inventor: Jean-Michel Vernier
-
Patent number: 9822122Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: March 16, 2017Date of Patent: November 21, 2017Assignee: Oncternal Therapeutics, Inc.Inventor: Stephen E. Webber
-
Patent number: 9604927Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.Type: GrantFiled: October 7, 2015Date of Patent: March 28, 2017Assignee: Oncternal Therapeutics, Inc.Inventor: Jean-Michel Vernier